ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ensysce Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.50−0.02 (-2.97%)

Close on Oct 19, 2026

Market cap: $6.56M
P/E (TTM): –
Dividend yield: –

Ensysce Biosciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	5.07	5.21	2.23	2.52	3.53	3.93	–	–
Research & Development	10	7.22	7.59	20	4.69	4.39	–	–
Selling, General & Admin	–	–	–	–	19	1.15	–	–
General & Administrative	4.93	4.72	5.36	6.91	19	–	–	–
Operating Expenses	15	12	13	27	23	5.54	3.33	1.56
Operating Income	-10	-6.73	-11	-24	-20	-1.61	-3.33	-0.96
Interest Expense	0.02	1.29	0.35	0.11	1.30	1.00	–	–
Interest & Investment Income	–	–	–	–	–	0.72	4.25	3.63
Other Non-Operating Income	0.06	-1.26	0.09	0.01	-9.28	1.45	–	–
Gain (Loss) on Sale of Assets	–	–	–	0.00	–	–	–	–
Pretax Income	–	–	–	–	–	4.56	-0.51	2.68
Income Tax Expense	–	–	–	–	–	0.24	0.56	0.55
Net Income incl. Noncontrolling Interests	-10	-7.99	-11	-24	-29	-0.16	-1.07	2.05
Minority Interest in Earnings	0.00	0.00	-0.01	-0.04	-0.06	-0.22	–	–
Net Income	–	–	–	–	–	4.31	-1.07	2.12
Net Income to Common	-10	-7.99	-11	-25	-30	0.06	-2.87	-1.34
EPS (Basic)(per share)	-3.98	-11.45	-70.40	-2,091.30	-444.60	0.00	-4.20	-1.40
EPS (Diluted)(per share)	-3.98	-11.45	-70.40	-2,091.30	-22.20	0.00	-4.20	-1.40
Shares Outstanding (Basic, Weighted)(shares)	2.56	0.70	0.15	0.01	0.07	1.05	0.99	0.99
Shares Outstanding (Diluted, Weighted)(shares)	2.56	0.70	0.15	0.01	1.34	1.10	0.99	0.99
Provision for Credit Losses	–	–	0.00	0.00	0.00	0.00	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -281.3%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.70
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 16.6%

Valuation

P/E ratio: –
Price to sales: 1.46
Price to book: –
Dividend yield: –